<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02425137</url>
  </required_header>
  <id_info>
    <org_study_id>TTYTG1308</org_study_id>
    <nct_id>NCT02425137</nct_id>
  </id_info>
  <brief_title>A Study of S-1 in Combination With Gemcitabine as First-Line Treatment in Patients With Advanced Biliary Tract Cancer</brief_title>
  <official_title>A Study of S-1 in Combination With Gemcitabine as First-Line Treatment in Patients With Advanced Biliary Tract Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>TTY Biopharm</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cheng-Kung University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Taiwan University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Taipei Veterans General Hospital, Taiwan</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chang Gung Memorial Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>TTY Biopharm</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary Objective:&#xD;
&#xD;
      To evaluate disease control rate (DCR) of S-1 in combination with gemcitabine in patients&#xD;
      with advanced biliary tract cancer&#xD;
&#xD;
      Secondary Objectives:&#xD;
&#xD;
        -  To evaluate overall response rate (ORR)&#xD;
&#xD;
        -  To evaluate progression-free survival (PFS)&#xD;
&#xD;
        -  To evaluate overall survival (OS)&#xD;
&#xD;
        -  To assess the safety profile&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2015</start_date>
  <completion_date type="Actual">May 2017</completion_date>
  <primary_completion_date type="Actual">May 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease control rate (DCR)</measure>
    <time_frame>2 years</time_frame>
    <description>Disease control is defined as having confirmed complete or partial response or stable disease</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective response rate (ORR)</measure>
    <time_frame>2 years</time_frame>
    <description>To assess Objective response rate (ORR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>progression-free survival (PFS)</measure>
    <time_frame>2 years</time_frame>
    <description>To assess progression-free survival (PFS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival (OS)</measure>
    <time_frame>2 years</time_frame>
    <description>To assess overall survival (OS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>safety profile (percentage of patients with at least one occurrence of preferred term will be included,according to the most severe NCI-CTCAE v4.03 grade)</measure>
    <time_frame>2 years</time_frame>
    <description>The incidence and percentage of patients with at least one occurrence of preferred term will be included,according to the most severe NCI-CTCAE v4.03 grade</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">51</enrollment>
  <condition>Advanced Biliary Tract Cancer(BTC)</condition>
  <arm_group>
    <arm_group_label>S-1/Gemcitabine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single-arm</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>S-1/Gemcitabine</intervention_name>
    <description>Eligible patients will receive gemcitabine 800 mg/m2/day on day 1 and S-1 orally 80-120 mg/day (depending on patient's body surface area (BSA)) on day 1 to 10 in a 2-week cycle.</description>
    <arm_group_label>S-1/Gemcitabine</arm_group_label>
    <other_name>TS-1/Gemmis</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  1.histologically confirmed biliary tract carcinoma (including intrahepatic bile duct,&#xD;
             extrahepatic bile duct, gallbladder, and ampulla of vater);&#xD;
&#xD;
          -  2.metastatic or unresectable disease;&#xD;
&#xD;
          -  3.no history of chemotherapy or radiotherapy for biliary tract cancer;&#xD;
&#xD;
          -  4.presence of at least one measurable tumor lesion which is defined as lesions that&#xD;
             can be accurately measured in at least 1 dimension with longest diameter (LD) ≥20 mm&#xD;
             using conventional techniques or ≥10 mm with spiral CT and MRI; measurable lymph nodes&#xD;
             must be ≥15 mm in the short axis;&#xD;
&#xD;
          -  5.adequate hematopoietic function which is defined as below:&#xD;
&#xD;
               1. hemoglobin level ≥ 9 g/dL;&#xD;
&#xD;
               2. absolute neutrophil count (ANC) ≥ 1,500/mm3;&#xD;
&#xD;
               3. platelet count ≥ 100,000/mm3;&#xD;
&#xD;
          -  6.adequate hepatic function which is defined as below:&#xD;
&#xD;
               1. total bilirubin ≤ 1.5 times upper limit of normal (ULN) and &lt; 2 mg/dL, or total&#xD;
                  bilirubin &lt; 3 mg/dL if biliary drainage was performed;&#xD;
&#xD;
               2. Alanine aminotransferase (ALT) ≤ 3 x ULN or ALT ≤ 5 x ULN in the presence of&#xD;
                  liver metastasis;&#xD;
&#xD;
          -  7.adequate renal function: creatinine clearance rate (CCr) ≥ 60 mL/min ((based upon&#xD;
             24-hour urine collection or calculated by Cockroft-Gault formula);&#xD;
&#xD;
          -  8.age of 20 years or above;&#xD;
&#xD;
          -  9.ECOG performance status 0-1;&#xD;
&#xD;
          -  10.life expectancy of at least 12 weeks;&#xD;
&#xD;
          -  11.ability to take oral medication;&#xD;
&#xD;
          -  12.ability to understand and willingness to sign a written informed consent document.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  1.other malignancy within the past 5 years except for adequately treated basal or&#xD;
             squamous cell skin cancer or cervical cancer in situ;&#xD;
&#xD;
          -  2.history or known presence of brain metastasis;&#xD;
&#xD;
          -  3.presence of grade 2 or above ascites or pleural effusion;&#xD;
&#xD;
          -  4.presence of grade 2 or above diarrhea;&#xD;
&#xD;
          -  5.presence of mental disease or psychotic manifestation;&#xD;
&#xD;
          -  6.active or uncontrolled infection;&#xD;
&#xD;
          -  7.significant medical conditions that is contraindicated to study medication or render&#xD;
             patient at high risk from treatment complications based on investigator's discretion;&#xD;
&#xD;
          -  8.pregnant women or nursing mothers, or positive pregnancy test for women of&#xD;
             childbearing potential. Patients with childbearing potential shall have effective&#xD;
             contraception for both the patient and his or her partner during the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Li-Tzong Chen, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Institute of Cacer Research, National Health Research Institiutes</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Chang Gung Memorial Hospital</name>
      <address>
        <city>Linkou</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Cheng Kung University Hospital</name>
      <address>
        <city>Tainan</city>
        <zip>704</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>100</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Taipei Veterans General Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov.tw/TC/index.aspx</url>
    <description>TFDA</description>
  </link>
  <results_reference>
    <citation>Morizane C, Okusaka T, Mizusawa J, Takashima A, Ueno M, Ikeda M, Hamamoto Y, Ishii H, Boku N, Furuse J. Randomized phase II study of gemcitabine plus S-1 versus S-1 in advanced biliary tract cancer: a Japan Clinical Oncology Group trial (JCOG 0805). Cancer Sci. 2013 Sep;104(9):1211-6. doi: 10.1111/cas.12218. Epub 2013 Jul 25.</citation>
    <PMID>23763511</PMID>
  </results_reference>
  <verification_date>July 2017</verification_date>
  <study_first_submitted>March 26, 2015</study_first_submitted>
  <study_first_submitted_qc>April 22, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 23, 2015</study_first_posted>
  <last_update_submitted>August 20, 2019</last_update_submitted>
  <last_update_submitted_qc>August 20, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 21, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Biliary Tract Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

